Park Place Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Park Place Capital’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-98	Closed	-$12.9K	–	883
2025 Q1	$12.9K	Hold	98	–	–	﹤0.01%	534
2024 Q4	$8.19K	Hold	98	–	–	﹤0.01%	609
2024 Q3	$7.17K	Hold	98	–	–	﹤0.01%	667
2024 Q2	$6.71K	Hold	98	–	–	﹤0.01%	674
2024 Q1	$6.78K	Hold	98	–	–	﹤0.01%	704
2023 Q4	$7.02K	Buy	98 +27	+38%	+$1.55K	﹤0.01%	680
2023 Q3	$3.7K	Hold	71	–	–	﹤0.01%	880
2023 Q2	$4.5K	Hold	71	–	–	﹤0.01%	875
2023 Q1	$3.85K	Hold	71	–	–	﹤0.01%	890
2022 Q4	$4K	Buy	+71	New	+$3.56K	﹤0.01%	898

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Park Place Capital's ITCI Position: Q2 2025 in Review

Park Place Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 98 shares — an estimated $12.9K sold.

Park Place Capital first reported a position in ITCI in Q4 2022 and held it in 10 quarters. The position peaked at $12.9K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Park Place Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Park Place Capital sold 98 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $12.9K.
Park Place Capital first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 10 quarters.
Park Place Capital's Intra-Cellular Therapies Inc. position peaked at $12.9K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Park Place Capital's 13F filing for Q2 2025, filed 17 Jul 2025.